Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-label Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Patients With Partial Onset Seizures With or Without Secondary Generalization

Next Previous
Search
Trial Profile

Multicenter, Open-label Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Patients With Partial Onset Seizures With or Without Secondary Generalization

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary) ; Carbamazepine; Lamotrigine; Levetiracetam; Oxcarbazepine; Valproic acid
  • Indications Partial epilepsies; Seizures; Tonic-clonic epilepsy
  • Focus Therapeutic Use
  • Acronyms FAME
  • Sponsors Eisai Korea

    • Most Recent Events

    • 06 Dec 2022 Results assessing the perampanel efficacy and safety data in older adult patients from Studies 412 (NCT02726074; FAME; Korea) and 501 (NCT04257604; AMPA; Italy) who received perampanel as a first or second adjunctive ASM, presented at the 76th Annual Meeting of the American Epilepsy Society.
    • 06 Dec 2022 Results of pooled analysis (n=253 from four studies NCT02726074, NCT04257604, NCT03288129, NCT04202159) assessing the efficacy and safety of perampanel as a first/only adjunctive ASM in patients with Focal-onset Seizures (FOS) or Generalized Tonic-clonic Seizures presented at the 76th Annual Meeting of the American Epilepsy Society
    • 23 Nov 2022 According to an Eisai Inc media release , data from this study will be presented at the 76th American Epilepsy Society Annual Meeting (AES 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top